NEW YORK (GenomeWeb News) – Cell-analysis tool company Fluxion Biosciences said today that it has expanded its sales and service network into Asia through a pair of distribution agreements and an instrument sale.
Fluxion, based in South San Francisco, Calif., said that it signed a distribution agreement for its BioFlux instrument line with Korea's DI Biotech, and a second agreement with Novel Science to sell both the BioFlux and IonFlux platforms in Japan.
Fluxion also said that it has sold its first BioFlux 1000 system in China to the China Academy of Chinese Medical Science, which will initially use the system to study inhibition of thrombus formation on endothelial cells.
The BioFlux platform enables live-cell image analysis for physiologically-relevant shear flow assays in a standard well-plate format. Ideal applications include research in cell and platelet adhesion, cancer biology, stem cells, and microbial biofilms.
IonFlux combines Fluxion’s microfluidic technology with integrated electronics to automate the traditional patch clamp assay for ion channel research. Ideal drug-discovery applications include primary and secondary screening, lead optimization, and toxicology screening, Fluxion said.